for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Immunomedics, Inc.

IMMU.O

Latest Trade

15.82USD

Change

0.38(+2.46%)

Volume

1,129,849

Today's Range

15.46

 - 

15.95

52 Week Range

11.55

 - 

24.99

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
15.44
Open
15.56
Volume
1,129,849
3M AVG Volume
47.78
Today's High
15.95
Today's Low
15.46
52 Week High
24.99
52 Week Low
11.55
Shares Out (MIL)
191.98
Market Cap (MIL)
2,964.15
Forward P/E
-9.43
Dividend (Yield %)
--

Latest Developments

More

Immunomedics Q2 Loss Per Share $0.40

Immunomedics Reports Q1 Results

Immunomedics Inc - Michael Pehl Has Stepped Down From Role Of President, CEO And Member Of Board

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Immunomedics, Inc.

Immunomedics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing monoclonal antibody-based products for the targeted treatment of cancer. Its technologies allow it to create humanized antibodies that can be used either alone in unlabeled or naked form, or conjugated with radioactive isotopes, chemotherapeutics, cytokines or toxins. It has a pipeline of six clinical-stage product candidates. Its portfolio of investigational products includes antibody-drug conjugates (ADCs) that are designed to deliver a payload of a chemotherapeutic directly to the tumor, while the managing overall toxic effects that are found with conventional administration of these chemotherapy agents. Its ADCs are sacituzumab govitecan (IMMU-132) and labetuzumab govitecan (IMMU-130). The Company also has a range of other product candidates that target solid tumors and hematologic malignancies, as well as other diseases, in various-stages of clinical and pre-clinical development.

Industry

Biotechnology & Drugs

Contact Info

300 the American Rd

+1.973.6058200

https://www.immunomedics.com/

Executive Leadership

Behzad Aghazadeh

Executive Chairman of the Board

Usama Malik

Chief Financial Officer

Kurt J. W. Andrews

Chief Human Resource Officer

Morris Z. Rosenberg

Chief Technology Officer

William Fricker

Principal Accounting Officer

Key Stats

2.00 mean rating - 10 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2016

0.0K

2017

0.0K

2019(E)

0.0K
EPS (USD)

2016

-0.680

2017

-1.470

2019(E)

-1.638
Price To Earnings (TTM)
--
Price To Sales (TTM)
--
Price To Book (MRQ)
25.64
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
6.13
LT Debt To Equity (MRQ)
6.13
Return on Investment (TTM)
-60.85
Return on Equity (TTM)
-56.24

Latest News

Latest News

Immunomedics' cancer treatment fails to win accelerated approval from the FDA

Immunomedics Inc said on Thursday the U.S. Food and Drug Administration declined to grant accelerated approval for its breast cancer treatment, sacituzumab.

BRIEF-Immunomedics Submits Biologics License Application For Sacituzumab Govitecan To The U.S. FDA

* IMMUNOMEDICS SUBMITS BIOLOGICS LICENSE APPLICATION FOR SACITUZUMAB GOVITECAN TO THE U.S. FOOD AND DRUG ADMINISTRATION

BRIEF-Immunomedics Announces Promising Data Of Sacituzumab Govitecan In Estrogen Receptor-Positive Metastatic Breast Cancer

* IMMUNOMEDICS ANNOUNCES PROMISING DATA OF SACITUZUMAB GOVITECAN IN ESTROGEN RECEPTOR-POSITIVE METASTATIC BREAST CANCER Source text for Eikon: Further company coverage:

BRIEF-Immunomedics Reports Q3 Loss Per Share $0.21

* IMMUNOMEDICS ANNOUNCES THIRD QUARTER FISCAL 2018 RESULTS AND PROVIDES CORPORATE UPDATE

BRIEF-Immunomedics Q2 Loss Per Share $0.02

* IMMUNOMEDICS ANNOUNCES SECOND QUARTER FISCAL 2018 RESULTS AND PROVIDES CORPORATE UPDATE

BRIEF-Immunomedics Announces Agreement With University Of Wisconsin Carbone Cancer Center To Expand Sacituzumab Govitecan Into Prostate Cancer

* IMMUNOMEDICS ANNOUNCES AGREEMENT WITH UNIVERSITY OF WISCONSIN CARBONE CANCER CENTER TO EXPAND SACITUZUMAB GOVITECAN (IMMU-132) INTO PROSTATE CANCER

BRIEF-Immunomedics, Royalty Pharma Announce Royalty Funding And Stock Purchase Agreements Totalling $250 Mln

* IMMUNOMEDICS AND ROYALTY PHARMA ANNOUNCE ROYALTY FUNDING AND STOCK PURCHASE AGREEMENTS TOTALLING $250 MILLION

BRIEF-Immunomedics appoints Michael Pehl president and CEO

* Immunomedics appoints Michael Pehl president and chief executive officer to lead next phase of transformative growth

BRIEF-Immunomedics announces first quarter fiscal results

* Immunomedics announces first quarter fiscal 2018 results and provides corporate update

BRIEF-Immunomedics to exchange about $80 mln of its 4.75 pct Convertible Senior Notes due 2020 for common stock

* Immunomedics announces agreements to exchange approximately $80.0 mln of its 4.75 pct Convertible Senior Notes due 2020 for common stock

BRIEF-Immunomedics presents interim phase 2 results with sacituzumab govitecan (i

* Immunomedics presents interim phase 2 results with sacituzumab govitecan (immu-132) in patients with pretreated metastatic urothelial cancer Source text for Eikon: Further company coverage:

BRIEF-Immunomedics announces publication of cancer drug data

* Immunomedics announces publication of phase 2 results with labetuzumab govitecan (immu-130) that demonstrate promising efficacy as a single agent in patients with metastatic colorectal cancer

BRIEF-Immunomedics reports Q4 loss per share $0.48

* Immunomedics announces fiscal 2017 results and strategic developments; reiterates guidance on bla submission timeline

BRIEF-Immunomedics files for offering of 34.8 mln shares of common stock by selling stockholders

* Immunomedics files for offering of 34.8 million shares of common stock by selling stockholders - sec filing

BRIEF-Immunomedics files for 34.8 mln shares of co's common stock

* Files for 34.8 million shares of co's common stock by the selling stockholders - sec filing

BRIEF-Seattle Genetics reports 8.2 percent stake in Immunomedics as of June 29, 2017

* Seattle genetics inc reports a 8.2 percent stake in immunomedics inc as of June 29, 2017 - sec filing

BRIEF-Immunomedics Q3 loss per share $0.55

* Immunomedics announces third quarter fiscal 2017 results and clinical program developments

BRIEF-Immunomedics announces private placement offering

* Immunomedics delivers business updates, announces private placement offering and outlines strategic steps to drive stockholder value

BRIEF-Seattle Genetics terminates license agreement with Immunomedics

* Seattle Genetics terminates license agreement with Immunomedics for sacituzumab govitecan (immu-132)

BRIEF-Seattle Genetics says court issued temporary restraining order enjoining taking action in furtherance of closing of license agreement with Immunomedics

* Seattle Genetics- On March 9,court issued temporary restraining order enjoining taking action in furtherance of closing of license agreement with Immunomedics

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up